More precise mitotic count and estrogen/progesteron (ER/PR) scoring system impact on grading in pre- and post-neoadjuvant primary breast cancer: morphological, clinical and radiological assessment

Background: Breast cancer molecular subtypes (Luminal A and B, Triple negative, Her2-enriched) together with histology-based parameters (i.e. grading) are pivotal in understanding how tumor response is related to relapse risk and would help clinicians make decisions about additional treatment options after neoadjuvant chemotherapy (NCT). Different methods can be used to assess ER/PR status (Allred score, H score, semiquantitative score). Mitotic index (MI) can be performed on conventional histology or by using immunohistochemistry for phosphohistone H3 (PHH3).

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: C. Giacometti, M. Beda, A. Bellan, L. Vidotto, S. Ghiretti, L. Poletto, D. Pizzato, M. Maino, S. Duodeci, S. Zanovello, T. Mancuso, P. Bianchi, M. Cassaro Tags: POSTERS A: Optimal Diagnosis Source Type: research